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There is randomised study evidence that narrowband ultraviolet B (NB-UVB) is effective 
for eczema.1   A small controlled study did not detect an efficacy difference between bath 
8-MOP PUVA (psoralen drug with the main effects limited to the skin as the drug is
‘activated’ there by ultraviolet A [UVA] exposure) and NB-UVB.2 Another small 
randomised study showed that 5-MOP oral PUVA worked better than medium-dose 
ultraviolet A1 (UVA1).3  A systematic review concluded that NB-UVB and ultraviolet A1 
were the most effective phototherapies for eczema and pointed out the limited 
comparative evidence regarding PUVA.4
To guide our clinical use of the phototherapies, we assessed retrospectively the response 
to phototherapy (NB-UVB, UVA1 and PUVA) of atopic eczema in Tayside. This was part 
of local audit so Ethics committee approval was not needed.
We examined our local data, collected through PhotoSys (the database of the National 
Managed Clinical Network for Phototherapyhttps://www.photonet.scot.nhs.uk/ ) on 1532 
(88%) NB-UVB, 83 (4%) PUVA and 129 (6%) UVA1 whole-body courses given to 1303 
patients, with courses completed between February 2002 and January 2016. These 
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courses were given in 4 units (Dundee, Perth, Stracathro and St Andrews): all used NB-
UVB (broadband UVB stopped being used in Tayside before 1990) and PUVA (oral, 
predominantly 8-MOP, and bath 8-MOP [rarely used for eczema as face usually needs 
treated]) but UVA1 was only available in Dundee. All units are part of the same 
phototherapy service, with treatment protocols identical in all parts of the service.
We took “moderate improvement”, “minimal residual activity” or “cleared” recorded in 
Photosys as representing a good outcome and any other outcome (including “did not 
attend”) as not a good outcome. The main outcome measure we assessed was 
probability of a “good outcome” over number of treatments per course. We assessed 
many covariates (Table 1) that might influence treatment efficacy. We used the chi-
square test to compare proportions of discrete covariates and propensity scores were 
implemented with respect to the age and sex (variables hypothesized to be associated 
with both selected predictors and outcome).  It was verified that the proportions and 
propensity scores were statistically balanced across all covariates’ groups in the original 
study cohort. For simple comparison of “survival curves” we used the logrank test. We 
used multivariate (adjusting for sex and age, as recorded factors that might influence 
efficacy) frailty models for associations between the selected covariates and the 
probability of good outcome over the number of treatments per course, taking into 
account the correlation between outcomes of repeated courses within individuals..5 
Furthermore, this  frailty model allowed us to incorporate both time variant covariates 
such as levels of cumulative UVB, PUVA, and UVA1 treatments and time invariant 
covariates such as the levels of skin photoype and gender.  All statistical analyses were 
performed using R software version 3.4 (https://www.r-project.org/). 
Most patients, 679 (74%), had one course, 175 (17%) had two, 46 (5%) of subjects had 
three and only 37 (4%) patients had more than three. The main findings are shown in 
Table 1. A total of 763 (59%), 272 (20%), 138 (10%), and 130 (9.9%) courses were 
conducted at Dundee, Perth, St Andrews, and Stracathro centres respectively, with good 
outcome proportions of 63.3%, 74.3%, 63%, and 69.2%.
We found PUVA associated with a greater chance of a good outcome than the other 
phototherapies, despite it nearly-always being a second- or third-line phototherapy. One 
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this was connected with it (Perth) being the second-longest established unit and the 
longest-established being Dundee, the only unit also offering UVA1, a treatment often 
reserved for particularly difficult to treat patients. A unit being longer-established will often 
mean that a lower proportion of courses are given according to protocols, with more 
individualisation of treatment regimens. It seems likely that more individualisation of 
courses might be beneficial. This is yet an untested hypothesis: we did not collect data on 
proportion of individualised versus by protocol courses given in each centre in this 
retrospective review.
Having a painful erythema recorded was associated with more good outcomes. However, 
when we analysed taking into account number of treatments this effect disappeared 
suggesting that here the chances of having an important erythema may simply have been 
a marker for having sufficient treatments to benefit. Similarly, older patients appeared to 
fare better until we took into account number of treatments. Perhaps older patients were 
less likely to stop attending early.
Lower compared with higher cumulative exposures to UVB, UVA1 and to PUVA 
(although possibly with PUVA a chance finding – see Table 1) were associated with 
better responses. This may be because of keeping trying the treatments in those for 
whom they do not work well or there could be a genuine tachyphylaxis effect with the 
treatments becoming less effective with repeated courses.
In this population all were of low (I to III) Fitzpatrick sun-reactive skin phototypes, those of 
skin phototype II were slightly more likely to respond than those of phototype I. Similarly, 
although this did not reach statistical significance (see Table 1) those of skin phototype III 
may have done better. In Tayside, starting doses are decided by minimal erythema doses 
(for UVB and UVA1) or minimal phototoxic dose (for PUVA) repeated for each course but 
different phototypes can be associated with differences in the development of tolerance – 
perhaps different regimens for those of different phototypes would help or we could 
consider other methods to adjust individual doses during treatment courses.6
This was a retrospective review in a single area. It has, however, led to some altered 
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after failure of NB-UVB. Testing various hypotheses generated by our findings should 
help improve the use of these treatments for eczema.
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Table 1. Summary of data on most important variables assessed for possible effects on 
treatment outcome when treating eczema with the phototherapies 
  Overall Distribution of courses according to 
the outcome  
RR (95% CI) for multivariate 
frailty model (probability of ‘good 
outcome’ by cumulative number 










P value  
Sex    0.44b 
0.40c 
 
Female 689 (53%) 234 (34%) 455 (66%)  1 
Male 614 (47%) 207 (34%) 407 (66%)  0.91 [0.76, 1.10] 
Mean age at 
time of course  
34 33 years 35 years 0.02b 
0.73c 
 
High age ≥ 
31.09 yrs 
(median) 
653 (0.50) 202(30.93) 451 (69.07)  1 
Low age 620 (0.50) 239 (36.77) 411 (31.54)  0.94 [0.79, 1.13] 
Erythema    0.004b 
0.60c 
 
No 1261 (0.97) 435 (34.50) 826 (65.50)  1 




   0.993b
0.001c 
 
I 875 (0.67) 297 (33.94) 578 (66.33)  1 
II 401 (0.30) 135 (33.36) 266 (66.44)  1.33 [1.09, 1.62] 
III 27 (0.02) 9 (33.84) 18 (66.67)  1.47 [0.77, 2.80] 
Treatment 
Centre 
   0.007b 
0.001c 
 
Dundee 763 (.59) 280 (36.70) 483 (63.30)  1 
Perth 272 (0.20) 70 (25.74) 202 (74.26)  2.03 [1.64, 2.51] 
St Andrews 138 (0.10) 51 (36.96) 87 (63.04)  1.28 [0.95, 1.72] 
Stracathro 130 (0.099) 40 (30.77) 90 (69.23)  1.11 [0.84, 1.47] 
Treatment 
Type 
   0.005b 
0001c 
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UVA1 86(0.06) 43 (50.00) 43 (50.00)  0.19 [0.11, 0.33] 
UVB 1156(0.88) 376 (32.53) 780 (67.47)  0.29 [0.19, 0.43] 
Cumulative 
UVB  
   0.001b 
0.001c 
 
High ≥ 48m 654 (50.19) 172 (26.30) 482 (73.70)  1 
Low 642 (49.27) 266 (41.43) 376 (58.57)  2.07[1.73, 2.47] 
Cumulative 
PUVA 
   0.830a 
0.095b 
 
High ≥ 28m 185 (14.20) 65 (35.14) 120 (64.86)   1 
Low 418 (32.08) 137 (32.78) 281 (67.22)  1.64[0.88, 1.55] 
Cumulative 
UVA1 
   0.001b 
0.001c 
 
High ≥ 33m 99 (7.6) 35 (35.35) 64 (64.65)  1 
Low 107 (8.2) 60 (56.07) 47 (43.93)  2.47[1.34, 4.54] 
a: (directly comparing proportions)  
b: (from a multivariate frailty model taking into account cumulative treatment numbers and 
adjusted by sex and age) 
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